

UNITED STATES PATENT AND TRADEMARK OFFICE

INITED STATES DEPARTMENT OF COMMERCE Juited States Patent and Trademark Office didress: COMMISSIONER OF PATENTS AND TRADEMARK Washington, D.C. 2023 1

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION N	
09/701,849	08/09/2000	Bruce L. Roberts	GAO116C 8453		
75	90 11/19/2002				
Deborah Duggan			EXAMINER		
Genzyme Corporation			ZEMAN, MARY K		
15 Pleasant Stre	et Connerter				
PO Box 9322		ART UNIT	PAPER NUMBER		
Framingham, MA 01701-9322					
			1631	7	
			DATE MAILED: 11/19/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-90C (Rev. 07-01)

Office Action Summary

Application No.		Applicant(s)		
09/701,849		ROBERTS ET AL.		
Examiner		Art Unit		
Mary K Zeman		1631		

Mary K Zeman 1631

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address -- Period for Reply

THE MAILING DATE - Extensions of time may be after SIX (6) MONTHS fro If the period for reply spector of NO period for reply is specified by the period for reply within the incomplete of the No period for reply within the incomplete period for the Normal Procedure of t	ATUTORY PERIOD FOR E OF THIS COMMUNICATE AT HIS COMMUNICATE AT HIS COMMUNICATE AT HE HIS COMMUNICATE AT HIS	CFR 1,136(a). In no ever tion. rs, a reply within the statul y period will apply and will	t, however, may a reply be ory minimum of thirty (30) expire SIX (6) MONTHS f	timely filed days will be considered timely. om the mailing date of this communicati NEO (35 U.S.C. & 133).	ion.
Status					
1) Responsive t	o communication(s) filed	on			
2a) This action is	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	This action is			
3) Since this ap closed in acc Disposition of Claims	plication is in condition for ordance with the practice	allowance except under <i>Ex parte</i> Qu	for formal matters rayle, 1935 C.D. 1	prosecution as to the ments 453 O.G. 213.	s is
•	is/are pending in the app	lication			
	ve claim(s) is/are v		sideration.		
5) Claim(s)		Manarawan monin oo			
6) Claim(s)					
6) ☐ Claim(s)					
,	are subject to restriction a	and/or election rea	uirement		
Application Papers			anomone.		
	on is objected to by the E				
	filed on is/are: a)[
Applicant may	y not request that any objecti	on to the drawing(s)	be held in abeyance	See 37 CFR 1.85(a).	
	drawing correction filed or			proved by the Examiner.	
	orrected drawings are requir		ice action.		
12)☐ The oath or de	claration is objected to by	the Examiner.			
Priority under 35 U.S.					
13) Acknowledgm	nent is made of a claim for	foreign priority un	der 35 U.S.C. § 11	9(a)-(d) or (f).	
a)□ All b)□ S	some * c) ☐ None of:				
	d copies of the priority do				
	d copies of the priority do				
apr	of the certified copies of t olication from the Internation ed detailed Office action for	onal Bureau (PCT	Rule 17.2(a)).	eived in this National Stage eived.	
				19(e) (to a provisional applic	ation).
a) 🔲 The trans	slation of the foreign languent is made of a claim for	age provisional ap	plication has been	received.	
Attachment(s)					
	Cited (PTO-892) 's Patent Drawing Revlew (PTO · Statement(s) (PTO-1449) Pape			mary (PTO-413) Paper No(s) mal Patent Application (PTO-152)	

Application/Control Number: 09/701,849

Art Unit: 1631

Election/Restrictions

This application is a **continuation** of an international application, and is therefore subject to US restriction practice, and **not** unity of invention.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-13, drawn to methods of identifying fragments of a gene, classified in class 702. subclass 19.
- II. Claims 14-19, drawn to methods of treatment with polynucleotides, classified in class 514, subclass 44.
- III. Claims 20-24, drawn to isolated polynucleotides, classified in class 536, subclass23.1.

The inventions are distinct, each from the other because of the following reasons:

Inventions III and I/ II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the polynucleotides can be used to recombinantly express proteins, or in genetic testing arrays, etc. The claims of Group III are not drawn to any particular nucleotide sequence, and the method of Group II does not require any particular nucleotide sequence. The claims of Group I do not identify any particular nucleotide sequence such that the methods must be practiced together. The claims of Group III are product-by-process claims, however, the process

Application/Control Number: 09/701,849

Art Unit: 1631

does not appear to impart any particular features upon the product. As such, the search of the inventions would pose an undue burden upon the examiner if not restricted.

Inventions I and II are independent and distinct as they are drawn to differing methods having differing steps and differing goals and using differing starting products. As such, search and examination of the two methods would require search and examination of disparate considerations in non-overlapping areas of technology, and would pose an undue burden upon the examiner if not restricted.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary K Zeman whose telephone number is (703) 305-7133.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached at (703) 308-4028.

Application/Control Number: 09/701,849

Art Unit: 1631

Official fax numbers for this Art Unit are: (703) 308-4242, (703) 872-9306. An unofficial fax number, direct to the Examiner is (703) 746 5279. Please call prior to use of this number.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the TC1600 Receptionist whose telephone number is (703) 308-0196.

mkz 11/15/02

> MARY K. ZEMAN PRIMARY EXAMINER

AU(63)